Skip to main content
GoodMoatv1.3
Sign in
ARWR logo

ARWR

CompareEarnings: May 31, 2026

Arrowhead Pharmaceuticals Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Did you know?

Capital expenditures decreased by 84% from FY24 to FY25.

Current Price

$74.81

+1.81%
Profile
Valuation (TTM)
Market Cap$10.16B
P/E50.23
EV—
P/B21.80
Shares Out135.81M
P/Sales9.31
Revenue$1.09B
EV/EBITDA29.30

Arrowhead Pharmaceuticals Inc (ARWR) Company Profile

ARWR Company Information

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.

Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

California, USA

ARWR Key Officers

Key officers data coming soon

ARWR Company Profile

Arrowhead Pharmaceuticals Inc (ARWR) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in California, USA.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Market cap is $10.16B. There are 135.8M shares outstanding.

See the full Arrowhead Pharmaceuticals Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if ARWR is a good investment.